BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

KemPharm, Inc. Presents Key Findings for Novel Hydromorphone Prodrug at 2012 International Conference on Opioids


6/11/2012 9:24:58 AM

NORTH LIBERTY, Iowa, June 11, 2012 (GLOBE NEWSWIRE) -- KemPharm, Inc. today presented key preclinical findings from KP511, the Company's first-in-class oral hydromorphone prodrug, at the 2012 International Conference on Opioids. KP511 exhibited superior pharmacological and physicochemical characteristics that may suggest an improved safety profile compared to currently marketed hydromorphone products, including potential reduction or elimination of opioid-induced constipation (OIC). KP511 may also limit abuse potential due to its inherent abuse-deterrent properties as a prodrug, as well as its tamper-resistant properties, which make it difficult to extract active hydromorphone from the prodrug until it is cleaved by natural enzymes in the body. The company expects to file an IND for KP511 in mid-2013 and anticipates conducting a Phase 1 clinical proof-of-concept trial shortly after.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES